We appreciate Hollenberg's interest in our article.1 As reported previously, participants were assigned to chlorthalidone (12.5-25 mg/d), amlodipine (2.5-10 mg/d), or lisinopril (10-40 mg/d). The distribution of doses prescribed at years 1, 3, and 5 are given in the Table. At year 1, the lowest dose was prescribed for 33.0%, 24.6% and 28.3% of the participants assigned to chlorthalidone, amlodipine, or lisinopril, respectively; the middle dose for 17.1%, 22.4%, and 15.2%; and the highest dose for 33.8%, 37.1%, and 34.3%. At year 5, the lowest dose was prescribed for 17.9%, 11.2%, and 14.0% of the participants, respectively; the middle dose for 12.9%, 13.9%, and 10.4%; and the highest dose for 40.8%, 47.6%, and 37.1%. Therefore, the majority of participants receiving lisinopril were receiving the higher dose levels of 20 mg or 40 mg during the course of the study. This pattern was consistent in participants with a baseline glomerular filtration rate less than 60 mL/min per 1.73 m2.